Antimicrobial, in vitro and in vivo antineoplastic activities, mechanism of action, structural and thermal properties of a small-novel pharmaceutical organometallic chelate

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 293-299

  Batarseh, Kareem I ^a,b  

^a Alpha Omega Biologicals   (United States)

^b NovaGene LLC   (United States)

Author keywords

Aliargentumycine (AAgM); Antimicrobial; Antineoplastic; Apoptosis; In vitro; In vivo; Silver(I) tartaric acid; Solid and disseminated tumors; Structural and thermal properties

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALIARGENTUMYCINE; ORGANOMETALLIC COMPOUND; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; SILVER; TARTARIC ACID; TARTARIC ACID DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER SURVIVAL; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LOW DRUG DOSE; NONHUMAN; REVIEW; THERMAL ANALYSIS; CHEMISTRY; CONFORMATION;

ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR CONFORMATION; ORGANOMETALLIC COMPOUNDS; SILVER; TARTRATES;

EID: 65349172968     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557510909030293     Document Type: Review

References (56)

1. Merluzzi, V.J.; Cipriano, D.; McNeil, D. Evaluation of zinc complexes on the replication of rhinovirus 2 in vitro. Res. Commun. Chem. Pathol. Pharmacol., 1989, 66, 425-40.
2. Slawson, R.M.; Van Dyke, M.I.; Lee, H.; Trevors, T.J. Germanium and silver resistance, accumulation, and toxicity in microorganisms. Plasmid, 1992, 27, 72-9.
3. Khurshid, H. Antimicrobial activity of iron (II) and zinc (II)-amino acid complexes. Pak. J. Pharmacol., 1996, 13, 41-5.
4. Klasen, H.J. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns, 2000, 26, 131-38.
5. + in Vibrio cholerae. Antimicrob. Agents. Chemother., 2002, 46, 2668-70.
6. Richard (III), J.W.; Spencer, B.A.; McCoy, L.F.; Carino, E.; Washington, J.; Edgar, P.; Rosenblatt, J.; Goodheart, R.; Heggers, J.P. Acticoat™ versus Silverlon®: the truth. J. Burns and Surg. Wound Care, 2002, 1, 11-18.
7. Credé, C.S.E. Die verhürtung der augenentzündung der neugeborenen. Archiv für Gynaekologie, 1881, 17, 50-3.
8. Heggers J.; Goodheart, R.; Washington, J.; McCoy, L.; Carino, E.; Dang, T.; Edgar, P.; Maness, C.; Chinkes, D. Therapeutic efficacy of three silver dressings in an infected animal model. J. Burn Care Rehabil., 2005, 2, 53-6.
9. South, J. Mild silver protein against internal and topical infections. www.smart-drugs.com/JamesSouth-silver.htm, 1999.
10. Wlodkowski, T.J.; Rosenkranz, H.S. Antifungal activity of silver sulfadiazine. Lancet, 1973, 2, 739-40.
11. Feder, B. Scientists resurrecting use of silver as antiseptic. The New York Times, December 2005.
12. Pil, P.; Lippard, S. In Encyclopedia of Cancer; Bertino, J. R., Ed.; Academic Press: San Diego, 1997; pp 392-410.
13. Jakupec, M.; Galanski, M.; Keppler, B. Tumor-inhibiting platinum complexes-state of the art and future perspectives. Rev. Physiol. Biochem. Pharmacol., 2003, 146, 1-53.
14. Haiduc, I.; and Silvestru, C. Rhodium, iridium, copper and gold antitumor organometallic compounds. In Vivo, 1989, 3, 285-93.
15. Caruso, F.; Rossi, M.; Tanski, J.; Sartori, R.; Sariego, R.; Moya, S.; Diez, S.; Navarrete, E.; Cingolani, F.; Pettinari, C. Synthesis, structure, and antitumor activity of a novel tetranuclear titanium complex. J. Med. Chem., 2000, 43, 3665-70.
16. Caruso, F.; Rossi, M.; Tanski, J.; Pettinari, C.; Marchetti, F. Antitumor activity of the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I). J. Med. Chem., 2003, 46, 1737-42.
17. Holler, E. In Metal Complexes in Cancer Chemotherapy; Keppler, B., Ed.; VCH Verlagsgesellschaft mbH: Weinheim, 1993; p 65.
18. Furst, A; Schlauder, M. Inactivity of two noble metals as carcinogens. J. Environ. Pathol. Toxicol., 1978, 1, 51-7.
19. Pedahzur, R.; Lev, O.; Fattal, B.; Shuval, H.I. The interactions of silver ions and hydrogen peroxide in the inactivation of E. coli: a preliminary evaluation of a new long acting residual drinking water disinfectant. Wat. Sci. Tech., 1995, 31, 123-9.
20. Demerec, M.; Bertani, G.; Flint, J. A survey of chemicals for mutagenic action on E. coli. Am. Nat., 1951, 85, 119-36.
21. Rossman, T.G.; Molina, M. The genetic toxicology of metal compounds: II. Enhancement of ultra violet light-induced mutagenesis in Escherichia coli WP2. Environ. Mutagen., 1986, 8, 263-71.
22. Nishioka, H. Mutagenic activities of metal compounds in bacteria. Mutat. Res., 1975, 31, 185-89.
23. Stillman, M.J.; Presta, A.; Gui, Z.; Jiang, D.T. Spectroscopic studies of copper, silver, and gold metallothioneins. Metal-Based Drugs, 1994, 1, 375-94.
24. Berners-Price, S.; Johnson, R.; Giovenella, A.; Faucette, L.; Mirabelli, C.; Sadler, P. Antimicrobial and anticancer activity of tetrahedral, chelated, diphosphine silver (I) complexes: comparison with copper and gold, J. Inorg. Biochem., 1988, 33, 285-95.
25. Newman, I.; Washburn, I. Ionic silver complex. US Patent No. 6, 838, 095, 2005.
26. 2 (acaH=9-anthracenecarboxylic acid): Synthesis, X-ray crystal structures, antimocrobial and anticancer activities. Inorg. Chem. Commun., 2007, 10, 1149-53.
27. National Cancer Institute. Cancer Screening Data. http://dtp.nci.nih.gov/ dtpstandard/servlet/MeanGraphSummary?searchtype= namecontains&chemnameboolean= and&outputformat=html&searchlist=silver&Submit=Submit
28. Batarseh, K.I. Anomaly and correlation of killing in the therapeutic properties of silver (I) chelation with glutamic and tartaric acids. J. Antimicrob. Chemother., 2004, 54, 546-48.
29. Batarseh, K.I. Apoptosis-inducing antineoplastic silver (I) coordination complexes. United States Patent Application No. 11/225, 565, 2006.
30. Batarseh, K.I. Apoptosis-inducing antineoplastic silver (I) coordination complexes. European Patent Application No. 1845997, 2007.
31. Batarseh, K.I. Apoptosis-inducing antineoplastic silver (I) coordination complexes. International Patent Application No. PCT/US 2006/000390, 2007.
32. Batarseh, K.I. Apoptosis-inducing antineoplastic silver (I) coordination complexes. Japanese Patent Application No. JP2007-550477, 2007.
33. Batarseh, K.I. A novel silver (I) chelate: cytotoxicity and apoptotic mechanism of action on human hematopoietic malignancies. Leukemia (Nature Publishing Group), 2008, 22, 448-50.
34. Batarseh, K.I. Antitumor activity, structural and thermal properties of a novel silver (I)-tartaric acid chelate. Poster Session and Proffered Talk Presented at the American Association for Cancer Research (AACR) International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, March 16-19, Dead Sea-Jordan, 2008.
35. Batarseh, K.I. A pharmaceutically small-novel organometallic complex: in vivo antineoplastic properties and kinetics on human hepatocellular carcinoma and acute myeloid leukemia. Submitted.
36. Darzynkiewicz, Z.; Bedner, E.; Traganos, F.; Murakami, T. Critical aspects in the analysis of apoptosis and necrosis. Hum. Cell, 1998, 1, 3-11.
37. Ferreira, C.; Epping, M.; Kruyt, F.; Giaccone, G. Apoptosis: target of cancer therapy. Clin. Cancer Res., 2002, 8, 2024-34.
38. Hengartner, M.O. The biochemistry of apoptosis. Nature, 2002, 407, 770-76.
39. Becker, R.; Selden, G. The Body Electric: Electromagnetism and the Foundation of Life, William Morrow & Company: New York, 1985.
40. Becker, R. Cross Current: The Promise of Electromedicine, the Perils of Electropollution, Penguin Group: New York, 1990.
41. Daskalakis, M.; Nguyen, T.; Nguyen, C.; Guldberg, P.; Köhler, G.; Wijermans, P.; Jones, P.; Lübbert, M. Demelthylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2'-deoxycytidine (decitabine) treatment. Blood, 2002, 100, 2957-64.
42. Sigalotti, L.; Altomonte, M.; Colizzi, F.; Degan, M.; Rupolo, M.; Zagonel, V.; Pinto, A.; Gattei, V.; Maio, M. 5-aza-2'-deoxycytidine (decitabine) treatment of hemotapoietic malignancies: a multimechanism therapeutic approach? Blood, 2003, 101, 4644-45.
43. Das, P.; Singal, R. DNA methylation and cancer. J. Clin. Oncol., 2004, 22, 4632-42.
44. Jabbour, E.; Kantarjian, H.; Garcia-Manero, G.; Issa, J. Decitabine in myelodysplastic syndromes. Future Drugs, 2005, 2, 835-42.
45. Karpf, A.; Lasek, A.; Ririe, T.; Hanks, A.; Grossman, D.; Jones, D. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol. Pharmacol., 2004, 65, 18-27.
46. Jain, R.K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev., 1990, 9, 253-66.
47. Forbes, N.S.; Munn, L.L.; Fukumura, D.; Jain, R. Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumor necrosis. Cancer Res., 2003, 63, 5188-93.
48. Znati, C.A.; Rosenstein, M.; Mckee, T.D.; Brown, E.; Turner, D.; Bloomer, W.; Watkins, W.S.; Jain, R.; Boucher, Y. Irradiation reduces interstitial fluid transport and increases the collagen content in tumors. Clin. Cancer Res., 2003, 9, 5508-13.
49. Jain, R.K. Molecular regulation of vessel maturation. Nat. Med., 2003, 9, 685-93.
50. Jain, R.; Booth, M.F. What brings pericytes to tumor vessels? J. Clin. Invest., 2003, 112, 1134-36.
51. Jain, R.K. In Clinical Oncology, 3rd ed; Abeloff, M., Armtage, J., Niederhuber, J., Kastan, M., McKenna, W., Eds.; Elsevier: Philadelphia, 2004; pp 153-72.
52. Slapak, C.A.; Kufe, D.W. In Harrison's Principles of Internal Medicine, 14th ed; Isselbacker, K. J., Ed.; McGraw-Hill: New York, 1998; pp 523-537.
53. Sweetman, S. C. Martindale: The Complete Drug Reference, 3rd Edition; Pharmaceutical Press: London-Chicago, 2002; pp 525-27.
54. ATSDR. Toxicological Profile for Silver. http://www.atsdr.cdc.gov/ toxprofiles/tp146-p.pdf, 1990.
55. IRIS. Silver. http://www.epa.gov/iris/subst/0099.htm, 1987.
56. Shapiro, G.; Harper, W. Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Invest., 1999, 104, 1645-53.